Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Oncology
Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
March 25th, 2008
ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) announced that complete safety data from its registrational bioequivalence clinical study of ANX-530 (vinorelbine emulsion) will be published in the 2008 Proceedings of the American Society of Clinical Oncology (ASCO) in connection with ASCO's 2008 Annual Meeting, which takes place May 30 - June 3, 2008 in Chicago, IL. The abstract, entitled "Tolerability and incidence of infusion site reactions with emulsion formulation of vinorelbine (ANX-530) compared to vinorelbine solution," will be published. ADVENTRX recently completed a registrational bioequivalence clinical study of ANX-530. Pharmacokinetic equivalence, the primary...
Source: Cancer Weekly (2008-03-25)
|
